Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Rodman & Renshaw Global Investor Conference 2015
29 slides from Stablecoin Development's conference presentation, Sep 14, 2015
Slide 1: Building a Commercial Portfolio of Differentiated Anti-Infective Eye Care Products
Building a Commercial Portfolio of Differentiated Anti-Infective Eye Care Products Rodman & Renshaw Global Investor Conference September 10, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements ‘This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will” “estimate,” “continue,” “anticipate,” “intend,”
Slide 3: Strategic Focus on Eye Care Aimed at Commercial Growth and Business Success
Strategic Focus on Eye Care Aimed at Commercial Growth and Business Success 1. Revenue growth from commercial products * Grow US. sales of Avenova™ © Capitalize on large opportunity in poorly served markets with FDA-cleared products 2. Innovation Daily » Announced FDA-cleared intelli-Case™ in June 2
Slide 4: White Blood Cell in Action: The Foundation of NovaBay Technology
— LESSEE White Blood Cell in Action The Foundation of NovaBay Technology Invading Microbe White Blood Cell a Red Blood Cells 6 Neutrox™ N-Chlorotaurine (NCT) ci~H — NovaBay’s proprietary, pure Natural compound Hypochlorous Acid solution Rapid acting, effective b) BUT unstable 4 N‘)vaBay
Slide 5: What is Blepharitis?
What is Blepharitis? Blepharon, Greek “eyelid” + itis — inflammatory disease © Signs and symptoms — Itchy, sore, red eyelids; eyelids stick together; burning, gritty sensation © High incidence ~ 37% of patients seen by ophthalmologists ~ 47% of patients seen by optometrists © Most common cause is st
Slide 6: Value Proposition — U.S. Launch of Prescription Avenova
~ Value Proposition — U.S. Launch of Prescription Avenova Addressing es a . REESE © 30 milion blepharitis and dry eye patients Market + 3 million cataract + 2 million refractive surgery patients (fuciesriizuis) * 45 medical reps in major U.S. markets oyWelric-|) * Ramp up to 50 reps = 80% market rea
Slide 7: Case Study — Compelling Results with Avenova
eS Case Study — Compelling Results with Avenova’
Slide 8: Avenova Ingredients: Pure Hypochlorous Acid + Saline
ee Avenova’ Ingredients = 1. Pure Hypochlorous Acid + 2. Saline “a Ee &FEE FE Lash Water, PEG-80 Sorbitan Laurate , Sodium. ‘Tricedeth Sulfate, PEG- 150 Distearate,, Disodium Lauroamphodiacetate, Cocamidopropy! Hydroxysultaine Sodium Laureth-13, Carboxyate , Sodium Chloride , Quaternium- 15 Water, P
Slide 9: Does not
Does not generate Resistance Mechanical Debridement Bacterial Removal MYWII E secon Anti-biofilm Activity Anti-Toxin
Slide 10: Avenova
a Avenova’ For the poorly served 30 million U.S. patients with blepharitis and MGD dry eye ily Lash Hygiene { = a A c Z z o
Slide 11: Avenova Market Coverage — Expanding to Reps
—— Avenova’ Market Coverage — Expanding to 50 Reps UcNorth, A-South ‘San Francisco, San Jose, Sacramento, San Diego, Seattle, Phoenix, Denver Memphis, St Louis, Atlanta, Baton Rouge, Dallas, Houston, ‘Austin, Kansas Cty, KS, Nashville, Oklahoma City Midwest: Chicago-No, Chicago-So, Detroit, Buffalo,
Slide 12: Avenova Launch Timeline
Thvenova Launch Timeline Expand Into Additional Int’| Markets
Slide 13: N@vaBay’
i N@vaBay’
Slide 14: Avenova Building Sales Momentum
as Avenova’ Building Sales Momentum Sales Ramping Up : ($000) Consecutive Quarter Growth 806 800 700 73% increase 2Q15 600 500 4 112% increase 1Q15 400 143% increase 4Q14 2 219 200 A oF 90 [| Earning pharmaceutical-like 100 - 20 margins [22 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 14 N@vaBay’ 900
Slide 15: Pharmacy Sales Continue to Grow
Pharmacy Sales Continue to Grow Avenova Wholesale Pharmacy Sales Nov. 17, 2014- Sept. 5, 2015 oo = sah oo a coms = aD emit cast @Mckesson a 1750, —Rolling 4-Wk Trend = as wand = - og 84 en 500 0330, tan on cory = ivi AMAL Fe re oF oF a pF oF wt ooo 15 N@vaBay’
Slide 16: KOL from Across U.S. Support Avenova
——~<L KOL from Across U.S. Support Avenova’ Ophthalmic Advisory Board Dr. Eric Donnenfeld Past president of Ocular Microbiology and Immunology Group and serves on the Board of Directors of ‘American Society of Cataract and Refractive Surgery. Dr. Donnenfeld has published over 175 journal articles, a
Slide 17: KOLs from Across U.S. Support Avenova
KOLs from Across U.S. Support Avenova’ Optometry Advisory Board Dr. Arthur Epstein Director of Dry Eye — Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; heads practice’s Dry-Eye — Ocular Surface Disease Center and serves as Director of Clinical Research. Internat
Slide 18: Collateral Marketing Materials
Collateral Marketing Materials 8 N@vaBay’
Slide 19: Avenova Interactive Website
Avenova Interactive Website io, Physician Finda Pharmacy 19
Slide 20: Therapeutic Area
Therapeutic Area Avenova Avenova Cream / Overnight Ointment intelli-Case N‘/®vaBay
Slide 21: intelli-Case
intelli-Case The first “smart case” for disinfecting contact lenses N@vaBay’
Slide 22: NovaClear with intelli-Case
“NovaClear with intelli-Case N@vaBay
Slide 23: intelli-Case — Safely Disinfecting Contact Lenses
intelli-Case — Safely Disinfecting Contact Lenses FDA-cleared high-tech device Uses hydrogen peroxide - the gold standard ~ Can irritate the eye or fail to kill bacteria if not used correctly © Potentially benefiting millions of contact lens users © Limited test marketing beginning in late 2015 with
Slide 24: (Aganocide)
(Aganocide) NeutroPhase (Neutrox) CelleRx (Neutrox) NovaBay Internal Market Research 2 Wound repair and regeneration: official publication of the Wound Healing Society and the European Tissue Repsir Society, Nih.gov. 2009 5 Assuming 3.6M US. procedures and CelleRx priced $50 /bottle = $180M market s
Slide 25: China Pioneer Pharma — March 2015 Launch in China
China Pioneer Pharma — March 2015 Launch in China Shipping 200,000 units to seed market Covered every province in China 510 Regional Distributors Covering 26,000 Hospitals Covering >95,000 Pharmacies 2 N®vaBay’
Slide 26: Management Team
Management Team * ! 4 Ron Najafi, Ph. ‘Tom Paulson Glenn Moro Russell Hoon CChief Executive Officer CChief Financial Officer __VP, Avenova Sales & Marketing, Senior Vice President (Aldrich, Rhone Poulenc (Abbott, Quidel,. Ciba-Corning, (Alcon) O%ylos, Tutogen, Integra) Rorer, Applied Biosystems) Neu
Slide 27: In Summary...Executing on Commercial Strategy
In Summary...Executing on Commercial Strategy e Revenue Growth e Adding more innovative products © Monetize non-core assets Focus on near-term revenue growth and ultimately profitability n N@vaBay’
Slide 28: Potential Key Inflection Points
ee Potential Key Inflection Points e Additional Ex. US partnership e 510k Rx products e intelli-Case test market launch e US alliances e Rx reimbursement from CMS e Full commercial impact of our 20 new reps © Monetization of our non-core assets 28 N@vaBay’
Slide 29: Building a Commercial Portfolio of Differentiated Anti-Infective Eye Care Products
Building a Commercial Portfolio of Differentiated Anti-Infective Eye Care Products Rodman & Renshaw Global Investor Conference September 10, 2015
NovaBay Pharmaceuticals — Rodman & Renshaw Global Investor Conference 2015 on 6ix